Adma Biologics Inc. (NASDAQ:ADMA) shares were up 7.8% during mid-day trading on Tuesday . The stock traded as high as $7.33 and last traded at $7.33, with a volume of 56,382 shares. The stock had previously closed at $6.80.

Separately, Maxim Group reaffirmed a “buy” rating and issued a $24.00 target price on shares of Adma Biologics in a report on Thursday, March 24th.

The firm’s 50-day moving average is $6.94 and its 200-day moving average is $6.43. The company’s market capitalization is $96.13 million.

Adma Biologics (NASDAQ:ADMA) last posted its quarterly earnings results on Friday, May 13th. The company reported ($0.43) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.37) by $0.06. Equities analysts anticipate that Adma Biologics Inc. will post ($1.03) EPS for the current fiscal year.

In other Adma Biologics news, Director Jerrold B. Grossman bought 45,769 shares of the company’s stock in a transaction on Tuesday, May 3rd. The shares were bought at an average cost of $6.50 per share, for a total transaction of $297,498.50. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Adam S. Grossman bought 200,000 shares of the company’s stock in a transaction on Tuesday, May 3rd. The shares were acquired at an average price of $6.50 per share, for a total transaction of $1,300,000.00. The disclosure for this purchase can be found here.

ADMA Biologics, Inc is a biopharmaceutical company that develops and manufactures specialty plasma-based biologics for the treatment and prevention of certain infectious diseases. The company’s targeted patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disorder or who may be immune-suppressed for medical reasons.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.